Genmab A/S (OCSE:GMAB) EV-to-Revenue : 6.10 (As of Apr. 25, 2024)

View and export this data going back to 2000. Start your Free Trial

What is Genmab A/S EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Genmab A/S's enterprise value is kr100,527 Mil. Genmab A/S's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was kr16,474 Mil. Therefore, Genmab A/S's EV-to-Revenue for today is 6.10.

The historical rank and industry rank for Genmab A/S's EV-to-Revenue or its related term are showing as below:

OCSE:GMAB' s EV-to-Revenue Range Over the Past 10 Years
Min: 5.97 Med: 18.99 Max: 69.87
Current: 6.1

During the past 13 years, the highest EV-to-Revenue of Genmab A/S was 69.87. The lowest was 5.97. And the median was 18.99.

OCSE:GMAB's EV-to-Revenue is ranked better than
54.36% of 1032 companies
in the Biotechnology industry
Industry Median: 7.64 vs OCSE:GMAB: 6.10

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-25), Genmab A/S's stock price is kr1972.00. Genmab A/S's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was kr249.87. Therefore, Genmab A/S's PS Ratio for today is 7.89.

Genmab A/S EV-to-Revenue Historical Data

The historical data trend for Genmab A/S's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S EV-to-Revenue Chart

Genmab A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

15.91

14.38

18.29

11.76

6.88

Genmab A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															11.76	9.52	8.87	8.10	6.88

Competitive Comparison of Genmab A/S's EV-to-Revenue

For the Biotechnology subindustry, Genmab A/S's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genmab A/S's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab A/S's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Genmab A/S's EV-to-Revenue falls into.

Genmab A/S EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Genmab A/S's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	100526.932	/	16474
	=	6.10

Genmab A/S's current Enterprise Value is kr100,527 Mil.
Genmab A/S's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr16,474 Mil.

Genmab A/S (OCSE:GMAB) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Genmab A/S's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	1972.00	/	249.867
	=	7.89

Genmab A/S's share price for today is kr1972.00.
Genmab A/S's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr249.87.

Genmab A/S EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Genmab A/S's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab A/S (OCSE:GMAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (OCSE:GMAB) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

GNMSF:USA GMAB:USA GMAB:Mexico GMABc:UK 0MGB:UK GE91:Germany

Address

Kalvebod Brygge 43, Copenhagen, DNK, 1560

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.